Peptide Reclassification: What Compounding Pharmacies Must Verify

Correction — September 6, 2026: An earlier version described a February 27 blanket reclassification, a May 28 effective date, and an enhanced-surveillance schedule without a supporting primary-source citation. Those claims have been removed. A Category 1 nomination is not blanket authorization to compound a substance.

Check the specific FDA pathway

A pharmacy should verify the exact bulk drug substance against the requirements for its own facility type. FDA maintains separate information for section 503A pharmacies and section 503B outsourcing facilities. Status under one pathway should not be assumed to establish eligibility under the other.

FDA describes Category 1 as substances under evaluation within its interim policies. The policy is conditional; it does not mean FDA has approved the resulting compounded drug. Consult the current substance entry and the applicable guidance together, rather than relying on a news headline or a supplier label.

503A and 503B are separate checks

For 503A, FDA explains the applicable bulk-substance requirements and the role of its interim policy while nominated substances are evaluated. Start with FDA’s 503A bulk-substance information. Record the exact identity, current status, and the conditions relevant to the proposed preparation.

For outsourcing facilities, use FDA’s separate 503B bulk-substance information. That page distinguishes Category 1 from substances with identified safety risks and explains that the interim policy applies only when its conditions are met. A 503A status entry does not replace this assessment.

Keep a reviewable decision record

Before changing a compounding program, organize the evidence your responsible pharmacist or quality team needs to review:

• The exact substance and proposed preparation, including relevant route and dosage-form details.
• The FDA source URL, the date checked, and a retained copy or reference to the reviewed material.
• The applicable facility pathway and an explanation of the conditions considered.
• Supplier qualification and lot-documentation requirements identified by the reviewer.
• Any necessary updates to facility procedures, training, environmental controls, and preparation records.
• The accountable reviewer, decision date, unresolved questions, and follow-up review trigger.

This is a documentation workflow, not an authorization checklist. FDA’s bulk-substance overview provides the starting framework; current federal requirements, applicable state rules, and professional review still determine the facility’s decision.

What CompliRx can help document

CompliRx connects controlled procedures, training evidence, environmental records, and follow-up work. Keep the regulatory assessment and its source evidence connected to the operational changes it supports. Software cannot establish that a peptide is eligible for compounding or replace the responsible reviewer’s decision.